We don't know whether the most recent response to this request contains information or not – if you are Phil Early please sign in and let everyone know.

Questions in relation to Breast Cancer Treatment

We're waiting for Phil Early to read a recent response and update the status.

Dear James Paget University Hospitals NHS Foundation Trust,

I would like to please request the following information with regards to Breast Cancer Treatment.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Thank you for answering these questions.

Yours faithfully,

Phil Early

Freedomofinformation, James Paget University Hospitals NHS Foundation Trust

Dear Phil,

 

Thank you for your request for information.

 

During the COVID-19 pandemic, our resources at times were diverted from
the usual compliance and information rights work to the effective long
term management of the virus and supporting the vaccination programme, in
line with the Government’s request.

 

Whilst we recognise that statutory timescales cannot be extended, I would
like to apologise at the outset that there is still likely to be a
significant delay in responding to you. Our operational staff continue to
focus on our patients and their care to support the recovery of services,
particularly those that have been waiting for long periods. This is
alongside ensuring that current restrictions continue to keep our staff
and patients safe, in line with national requirements.

 

We have received a significant number of requests in recent weeks. We are
working through them to enable responses to be provided as soon as we are
able to.

 

Many thanks

 

Ann Filby CG (Affiliated) MCIPR

Head of Corporate Affairs/Trust Secretary

James Paget University Hospitals NHS Foundation Trust

01493 452162

 

[1][email address]

[2]www.jpaget.nhs.uk

 

 

show quoted sections

Freedomofinformation, James Paget University Hospitals NHS Foundation Trust

1 Attachment

Dear Phil

 

Further to your Freedom of Information request which we received on  1
April 2022, please find attached the information you require.

 

The information supplied to you continues to be protected by the
Copyright, Designs and Patents Act 1988. You are free to use it for your
own purposes, including any non-commercial research you are doing and for
the purposes of news reporting. Any other reuse, for example commercial
publication, would require the permission of the copyright holder. Most
documents supplied by James Paget University Hospitals NHS Foundation
Trust will have been produced by government officials and will be Crown
Copyright. You can find details on the arrangements for re-using Crown
Copyright on HMSOnline at:
[1]http://www.hmso.gov.uk/copyright/licence...

 

Information you receive which is not subject to Crown Copyright continues
to be protected by the copyright of the person or organisation from which
the information originated. You must ensure that you gain their permission
before reproducing any third party (non-Crown Copyright) information.

 

If you have any queries about this email, please contact me. Do remember
to quote the reference number above in any future communications.

 

If you are unhappy with the service you have received in relation to your
request and wish to request a review of our decision, you should write to:

 

Medical Director,

James Paget University Hospitals NHS Foundation Trust,

Lowestoft Road,

Gorleston,

Great Yarmouth,

Norfolk,

NR31 6LA.

 

Many thanks

 

Ann Filby CG (Affiliated) MCIPR

Head of Corporate Affairs/Trust Secretary

James Paget University Hospitals NHS Foundation Trust

01493 452162

 

 

show quoted sections

We don't know whether the most recent response to this request contains information or not – if you are Phil Early please sign in and let everyone know.